Trial · NCT00704769
Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)
NCT00704769, Completed, Organon and Co; results first posted 2009-08-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299). Trials, record NCT00704769. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00704769
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)
- NCT number
- NCT00704769
- Status
- Completed
- Enrollment
- 591 participants, actual
- Lead sponsor
- Organon and Co
- Conditions
- Rhinitis
- Interventions
- Desloratadine (assigned by investigator as part of normal practice)
- First posted
- 2008-06-25
- Last updated
- 2022-02-09
- Results first posted
- 2009-08-11
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | Minimum of 7 days after initiation of desloratadine | An adverse event was defined in the protocol to include any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product (at any dose). Additionally, any event that is associated with or observed in conjunction with a product overdose (whether accidental or intentional) or a product abuse and/or withdrawal were also considered an adverse event. The investigator assessed the relationship of any adverse event as either unlikely, possibly, or probably related to the use of study drug based on available information and protocol guidelines. |
| Primary | General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments | Minimum of 7 days after initiation of desloratadine | Physicians judged the subjects as good, excellent, fair, or poor. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Adverse Events | Minimum of 7 days after initiation of desloratadine | Participants | NUMBER | |
| PRIMARY | General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments | Minimum of 7 days after initiation of desloratadine | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adverse Events | Desloratadine | Nausea | 3 | Participants | |
| Adverse Events | Desloratadine | Dizziness | 1 | Participants | |
| General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments | Desloratadine | Good | 350 | Participants | |
| General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments | Desloratadine | Excellent | 159 | Participants | |
| General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments | Desloratadine | Fair | 50 | Participants | |
| General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments | Desloratadine | Poor | 11 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Desloratadine | 591 | |
| Overall Study | COMPLETED | Desloratadine | 591 | |
| Overall Study | NOT COMPLETED | Desloratadine | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Desloratadine | ||
| Total, other adverse events | Desloratadine | 0 | 591 |
| Total, serious adverse events | Desloratadine | 0 | 591 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00704769
GET https://conductscience.org/api/trials/v1/NCT00704769/registered